It’s a good day for Lipitor. And a good day for Pfizer.
This morning, Pfizer announced that the U.S. FDA had granted Lipitor (atorvastatin) five new indications, including, “reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.”
This comes on the heels of a retrospective analysis using a managed care database showing a 14% reduction in the risk of cardiovascular events with Lipitor compared to simvastatin. This is real-world clinical outcomes.
The winds of change might be blowing, but it’s still not smooth sailing on East 42nd Street yet.